Evolution of the Average Target: Incyte Corporation

Evolution of the Target Price: Incyte Corporation

Changes in Analyst Recommendations: Incyte Corporation

9b5af9090695e41f.j53HurbCWMAoSgmKidy7arur0Ifti2sDRb1--j6ElGg.6ciIg4Ggbo1QHm3g07LJO-vm5s608yFuC_s0kRPU2QD_8bDM94dqiUINYg~3fd73209943f78e01a88279d6c3d2f92
17/04 Goldman Sachs Adjusts Incyte Price Target to $100 From $98, Maintains Neutral Rating MT
07/04 RBC Adjusts Price Target on Incyte to $95 From $92, Maintains Sector Perform Rating MT
24/03 UBS Lowers Price Target on Incyte to $94 From $104 MT
05/03 Evercore ISI Adjusts Price Target on Incyte to $110 From $73, Maintains In Line Rating MT
26/02 Argus Adjusts Price Target on Incyte to $115 From $100, Maintains Buy Rating MT
18/02 Barclays Adjusts Price Target on Incyte to $117 From $116, Maintains Overweight Rating MT
11/02 Deutsche Bank Adjusts Incyte Price Target to $98 From $70, Maintains Hold Rating MT
11/02 Stifel Adjusts Price Target on Incyte to $120 From $119, Maintains Buy Rating MT
11/02 TD Cowen Adjusts Price Target on Incyte to $123 From $128, Maintains Buy Rating MT
11/02 Goldman Sachs Adjusts Price Target on Incyte to $98 From $90, Maintains Neutral Rating MT
11/02 Morgan Stanley Raises Price Target on Incyte to $102 From $94, Keeps Equalweight Rating MT
11/02 RBC Cuts Price Target on Incyte to $92 From $95, Keeps Sector Perform Rating MT
10/02 Wells Fargo Adjusts Incyte Price Target to $101 From $107, Maintains Equal Weight Rating MT
06/02 Piper Sandler Adjusts Price Target on Incyte to $110 From $102, Maintains Overweight Rating MT
05/02 Barclays Adjusts Price Target on Incyte to $116 From $115, Maintains Overweight Rating MT
05/02 HC Wainwright Initiates Incyte at Buy With $135 Price Target MT
20/01 RBC Raises Price Target on Incyte to $95 From $92, Keeps Sector Perform Rating MT
20/01 Wells Fargo Downgrades Incyte to Equalweight From Overweight, Adjusts PT to $107 From $116 MT
16/01 Guggenheim Adjusts Price Target on Incyte to $130 From $125, Maintains Buy Rating MT
13/01 TD Cowen Adjusts Price Target on Incyte to $128 From $101, Maintains Buy Rating MT
08/01 Goldman Sachs Adjusts Price Target on Incyte to $90 From $80, Maintains Neutral Rating MT
08/01 RBC Raises Price Target on Incyte to $92 From $84, Keeps Sector Perform Rating MT
06/01 Morgan Stanley Adjusts Price Target on Incyte to $94 From $92, Maintains Equalweight Rating MT
24/12 Truist Adjusts Price Target on Incyte to $103 From $93, Maintains Hold Rating MT
11/12 Incyte's Blood Cancer Drug Program 'Looks Very Viable' Amid Development Challenges, RBC Says MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+10.78%
+16.82%
+9.9%
+40.01%
+43.58%
+14.19%
-15.55%
+3.63%
+31.09%
+17.09%
Average +17.15%
Weighted average by Cap. +20.17%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
96.22USD
Average target price
107.36USD
Spread / Average Target
+11.58%
High Price Target
135.00USD
Spread / Highest target
+40.30%
Low Price Target
71.00USD
Spread / Lowest Target
-26.21%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Goldman Sachs
RBC Capital Markets
UBS
Evercore ISI
Argus
Barclays
Deutsche Bank Securities
Stifel Nicolaus
Morgan Stanley
TD Cowen
Wells Fargo Securities
Piper Sandler
HC Wainwright
Guggenheim
Truist Securities
Leerink Partners
Mizuho Securities
Jefferies & Co.
Oppenheimer
BMO Capital
JPMorgan Chase
Wolfe Research
Citigroup
BofA Securities
William Blair & Co.
JMP Securities
SVB Securities LLC
Morningstar
Cowen
SVB Leerink
Benchmark Capital
Credit Suisse
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
96.22USD
Average target price
107.36USD
Spread / Average Target
+11.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. INCY Stock
  4. Consensus Incyte Corporation